RADNOR - NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the Company has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar.
Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday that it has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.
NRx Pharmaceuticals (NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted.
Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify.